Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Phibro Animal Health (PAHC)

Phibro sales rise 24% to $309.3 million in quarter; updates fiscal 2025 guidance

Positive Impact 3 of 5 earnings Written later

Phibro Animal Health reported second-quarter results for the period ended December 31, 2024, with net sales up 24% to $309.3 million and net income of $3.2 million, compared with $1.3 million a year earlier. The company also issued fiscal 2025 guidance that includes the Zoetis Medicated Feed Additive portfolio acquired on October 31, 2024, and the filing does not state how the new ranges compare with prior guidance.

Key points

  • Net income of $3.2 million, or $0.08 per diluted share, versus $1.3 million, or $0.03, a year earlier
  • Adjusted EBITDA of $48.2 million, up $18.7 million, or 64%
  • Fiscal 2025 guidance: net sales of $1.25 billion to $1.30 billion and adjusted EBITDA of $172 million to $180 million
  • Interest expense rose to $9.0 million from $4.7 million, due to higher debt tied to the acquisition

The filing

CompanyPhibro Animal Health (PAHC)
Form8-K, current report
Filed with the SECFeb 5, 2025, 4:43 PM ET
Accession number0001558370-25-000661

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.